Sex-Specific Association between Serum Uric Acid and Nonalcoholic Fatty Liver Disease in Type 2 Diabetic Patients
Table 1
Clinical and biochemical characteristics of the study subjects.
Characteristics
Women
Men
Non-NAFLD
NAFLD
value
Non-NAFLD
NAFLD
value
117
153
118
153
Age (years)
61.7 ± 13.0
59.6 ± 10.2
0.163
57.7 ± 13.7
53.9 ± 15.1
0.032
Duration (years)
7 (3–11)
3 (0–9)
<0.001
5 (0–10)
2 (0–6)
0.041
BMI (kg/m2)
22.8 ± 3.4
26.1 ± 3.6
<0.001
23.0 ± 2.9
26.1 ± 3.5
<0.001
SBP (mmHg)
134.4 ± 18.5
136.6 ± 18.3
0.335
133.1 ± 18.8
134.1 ± 17.3
0.634
DBP (mmHg)
79.4 ± 10.0
82.8 ± 10.8
0.009
81.6 ± 9.9
83.1 ± 11.4
0.242
FPG (mM)
9.2 ± 4.2
11.0 ± 3.5
<0.001
9.8 ± 3.5
11.1 ± 3.0
0.001
HbA1C (%)
10.4 ± 7.2
9.9 ± 2.3
0.49
10.3 ± 2.5
10.3 ± 2.1
0.99
TG (mM)
1.2 (0.9–1.6)
1.7 (1.3–2.5)
<0.001
1.2 (0.9–1.6)
1.8 (1.2–3.0)
<0.001
TC (mM)
4.8 ± 1.3
5.0 ± 1.2
0.204
4.6 ± 1.2
4.7 ± 1.4
0.4
LDL-C (mM)
3.1 ± 1.0
3.2 ± 1.1
0.171
3.0 ± 1.0
2.9 ± 1.0
0.652
HDL-C (mM)
1.5 ± 0.5
1.2 ± 0.3
<0.001
1.3 ± 0.4
1.1 ± 0.4
<0.001
ALT (IU/L)
9 (7–11)
13 (9–23)
<0.001
10 (8–14)
14 (10–23)
<0.001
AST (IU/L)
17 (15–20)
21 (16–29)
<0.001
17 (14–21)
20 (16–28)
<0.001
eGFR (mL/min/1.73 m2)
132 (112–160)
142 (116–170)
0.11
140 (112–161)
137 (115–167)
0.661
HOMA-IR
2.4 (1.5–4.1)
4.5 (3.0–7.2)
<0.001
2.4 (1.6–3.8)
3.9 (2.6–6.0)
<0.001
SUA (μM)
267.0 ± 88.2
275.7 ± 80.1
0.403
281.1 ± 80.3
334.1 ± 91.3
<0.001
Insulin therapy (%)
24.1
15.6
0.238
9.8
12.9
0.604
OADs therapy (%)
48.3
25
0.008
33.3
34.3
0.913
Continuous variables were presented as means ± SD or median (interquartile range), and categorical variables were displayed as percentages (%). OADs, oral antidiabetic drugs.
